Table 2 Treatment details
Chemo-naïve (n = 58) | Post-chemo (n = 52) | |
|---|---|---|
Median duration of AA treatment, month (range) | 6.8 (0.6–21.5) | 7.1 (0.5–25.0) |
PSA response (%) | ||
≥50 % PSA decline from baseline | 36 (62.1) | 26 (50.0) |
≥90 % PSA decline from baseline | 16 (27.6) | 8 (15.4) |
Median time to PSA nadir, month (range) | 3.1 (0.9–15.0) | 2.8 (0.5–15.3) |
PSA flare (%) | ||
No. of patients | 17 (29.3) | 15 (28.8) |
Presence of eventual PSA response (≥50 % PSA decline from baseline) | 12 (70.6) | 10 (66.7) |
Pain alleviation during or after AAa (%) | 11 (57.9 %) | 11 (68.8 %) |
Reasons of discontinuing AA (%) | ||
Disease progression | 24 (41.4) | 36 (69.2) |
Treatment-related complication | 3 (5.2) | 1 (1.9) |
Patient’s decision | 3 (5.2) | 2 (3.8) |
Unknown | 1 (1.7) | 0 |
Continuation of AA beyond PD | ||
No. of patients (%) | 13 (22.4) | 18 (34.6) |
Median time, month (range) | 2.8 (1.0–5.8) | 2.0 (1.2–16.2) |
Subsequent therapy after PD (%) | ||
Docetaxel | 5 (8.6) | 2 (3.8) |
Cabazitaxel | 2 (3.4) | 7 (13.5) |
Mitoxantrone | 0 | 1 (1.9) |
Ketoconazole | 0 | 1 (1.9) |